



ICD-10 & Other Coding Revisions to National Coverage Determinations: July 2025 Update

Related CR Release Date: June 25, 2025	MLN Matters Number: MM13939 Revised
Effective Date: July 1, 2025 – unless noted in individual Business Requirements (BRs)	Related Change Request (CR) Number: CR 13939
Implementation Date: April 21, 2025 – BRs 1, 2, 3, 4, 5, 7 & 8; July 7, 2025 – BRs 6 & 10 only	Related CR Transmittal Numbers: R13097OTN & R13286OTN
Related CR Title: International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to National Coverage Determinations (NCDs)—July 2025	

What's Changed? We made no substantive changes to the article other than to update the CR release date, CR link, and transmittal numbers.

Affected Providers

- Physicians
- Suppliers
- Other providers billing Medicare Administrative Contractors (MACs) for services they provide to Medicare patients

Action Needed

Make sure your billing staff knows about:

- Newly available codes
- Recent coding changes
- National Coverage Determination (NCD) coding information

Background

CR 13939 is a maintenance update of ICD-10 conversions and other coding updates specific to NCDs. These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.

Translations from ICD-9 to ICD-10 aren't consistent 1-to-1 matches, nor are all ICD-10 codes appearing in a complete General Equivalence Mappings mapping guide or other mapping guides appropriate when reviewed against individual NCD policies. Also, for policies that allow MAC discretion, NCDs may change based on current review of those NCDs against ICD-10 coding. For those reasons, some ICD-9 codes that were appropriate before ICD-10 implementation are no longer valid.

Relevant coding changes in CR 13939 include:

- NCD 80.2 — Photodynamic Therapy
- NCD 80.2.1 — Ocular Photodynamic Therapy (OPT)
- NCD 80.3 — Photosensitive Drugs
- NCD 80.3.1 — Verteporfin
- NCD 90.2 — Next Generation Sequencing (NGS)
- NCD 100.1 — Bariatric Surgery for Treatment of Co-Morbid Conditions Related to Morbid Obesity
- NCD 110.18 — Aprepitant for Chemotherapy-Induced Emesis
- NCD 110.23 — Stem Cell Transplantation
- NCD 110.24 — Chimeric Antigen Receptor (CAR) T-Cell Therapy
- NCD 160.18 — Vagus Nerve Stimulation (VNS)
- NCD 210.3 — Colorectal Cancer Screening Tests
- NCD 250.3 — Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases

[NCD coding changes](#) are available. We didn't include any policy changes in this ICD-10 quarterly update. We share NCD policy changes using the current, longstanding NCD process.

Your MAC will adjust any claims processed in error associated with CR 13939 that you bring to their attention.

More Information

We issued [transmittals R13097OTN and R13286OTN](#) to your MAC as the official instructions for this change. For more information, find your [MAC's website](#).

Document History

Date of Change	Description
June 26, 2025	We made no substantive changes to the article other than to update the CR release date, CR link, and transmittal numbers.
March 21, 2025	Initial article released.

View the [Medicare Learning Network® Content Disclaimer and Department of Health & Human Services Disclosure](#).

The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health & Human Services (HHS).

